CHAPEL HILL, N.C., Aug. 27, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP) today announced that Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will present at three upcoming investor conferences.
- Baird 2014 Health Care Conference at 8:30 a.m. EDT, Wednesday, Sept. 3, at The New York Palace hotel in New York City
- Morgan Stanley 2014 Global Healthcare Unplugged Conference at 9:45 a.m. EDT, Wednesday, Sept. 10, at the Grand Hyatt New York hotel in New York City
- The 21st Annual NewsMakers in the Biotech Industry conference at 11 a.m. EDT, Friday, Sept. 26, at the Millennium Broadway Hotel & Conference Center in New York City
About Cempra, Inc.
Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) is in Phase 3 clinical development for community-acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin also recently entered a Phase 3 clinical trial for uncomplicated Neisseria gonorrhoeae and chlamydia. Taksta™ (CEM-102) is Cempra's second product candidate, which completed a Phase 2 clinical trial for prosthetic joint infections. Both seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about Cempra can be found at www.cempra.com.